CartiCure

Company Overview

Snapshot

Founded in January 2006 by Gila Maor, CartiCure operates with 1–10 employees. The company is focused on developing cartilage repair products and has successfully completed pre-clinical studies in large and small animals, securing a granted US patent for its technology.

Business overview

CartiCure is an early-stage Health Tech & Life Sciences company specializing in the development of cartilage repair products. Its core technology generates original hyaline cartilage-producing cells for transplantation into damaged joints, aiming to efficiently replenish lesions in articular cartilage. The company's initial product, Cartimove, targets knee cartilage damage from trauma, with a next-generation product aimed at the osteoarthritis market. CartiCure operates within the Medical Devices sector, serving the healthcare industry, particularly providers and the medical equipment segment, with a focus on the United States market.

Company Intelligence Q&A

What is CartiCure's primary focus?

CartiCure is dedicated to the development of cartilage repair products, utilizing a technological platform that generates original hyaline cartilage-producing cells for transplantation into damaged joints.

Who founded CartiCure?

CartiCure was founded by Gila Maor in January 2006, who also serves as the company's CTO.

What is CartiCure's first product?

CartiCure's first product, Cartimove, is designed for the treatment of knee cartilage damage resulting from trauma injuries.

Where are CartiCure's scientific and animal trials conducted?

Scientific work and ongoing animal trials for CartiCure are conducted at the Faculty of Medicine at the Technion-Institute of Technology in Haifa, Israel.

What is the status of CartiCure's intellectual property?

CartiCure holds a strong IP portfolio, which includes a granted US patent for its technology.